Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.48 |
| ▸ | JAK2 | O60674 | 6/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | BRD2 | P25440 | 2/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030640 | 0.85 | PTK2 (0.59) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL11031274 | 0.83 | BRD4 (0.46) | BRD4JAK2JAK3PTK2SLC2A1 | |
| SCHEMBL11030430 | 0.83 | BRD4 (0.63) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL11029787 | 0.83 | JAK2 (0.47) | BRD4JAK2JAK3PTK2SLC2A1 | |
| SCHEMBL11032241 | 0.80 | BRD4 (0.46) | BRD4JAK2JAK3PTK2SLC2A1 | |
| SCHEMBL11029599 | 0.80 | MAPKAPK2 (0.58) | SLC2A1EGFRMAPKAPK2 | |
| SCHEMBL11029346 | 0.79 | MAPKAPK2 (0.61) | BRD4SLC2A1EGFRFLT3MAPKAPK2 | |
| SCHEMBL11026741 | 0.79 | FYN (0.55) | SLC2A1EGFRMAPKAPK2 | |
| SCHEMBL11031445 | 0.79 | SLC2A1 (0.51) | BRD4PTK2SLC2A1EGFRMAPKAPK2 | |
| SCHEMBL11027433 | 0.78 | MAPKAPK2 (0.60) | JAK2JAK3JAK1SLC2A1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | claimed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | claimed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | BRD4 1244/4885JAK2 83/4885JAK3 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.